- ￥4700
- GeneTex
- 美国
- GTX14145
- 2025年07月15日
- WB, ICC/IF, IHC-Fr, FACS, Neutralizing/Inhibition
- Rat
- Mouse
企业认证
相关产品推荐更多 >
![SGCE antibody [N1C1]](https://img1.dxycdn.com/2022/0328/529/5032278622971300453-14.jpg!wh200)
![Syndecan-1 / CD138 antibody [SDC1/4378R]](https://img1.dxycdn.com/2022/0328/725/0083070929749700453-14.jpg!wh200)
![MSR1 antibody [2F8] (Biotin)](https://img1.dxycdn.com/2022/0328/638/0371902693154400453-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 免疫原：
Mouse CD274
- 亚型：
IgG2b
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. Store at 4ºC. DO NOT FREEZE.
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Mouse
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
Mouse
- 目录编号：
GTX14145
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Rat
- 应用范围：
WB, ICC/IF, IHC-Fr, FACS, Neutralizing/Inhibition
- 浓度：
Batch dependent (Please refer to the vial label for the specific concentration.)
- 靶点：
PD-L1
- 抗体英文名：
PD-L1 antibody [10F.9G2]
- 抗体名：
PD-L1 抗体 [10F.9G2]
- 规格：
500 μg
WB analysis of purified PD-L1 recombinant protein using GTX14145 PD-L1 antibody [10F.9G2].
Lane 1 : 0.1 ug reduced purified mouse PD-L1 with histidine tag at C-terminuse
Lane 2 : 0.05 ug reduced purified mousePD-L1 with histidine tag at C-terminus
Dilution : 8 ug/ml
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Zheng F et al., BioMed Research International 2017 2017()
「神药」再显威！杨黄浩等让二甲双胍扮演 PD-L1 「单抗」角色，提高治疗效果
ICBs 的抗肿瘤效果。 该研究成果以 Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy. 为题，发表在了 2021 年 1 月 1 日的 Theranostics 上 [1]。 图片来源：Theranostics 研究内容：此前有研究报道，二甲双胍可以抑制肿瘤进展，改善癌症患者的预后和生存率。此外，也有研
Antibody-Directed Enzyme-Prodrug Therapy
and antibody engineering is now addressing these problems by allowing the creation of antibodies with required characteristics for specific purposes. Antibody-directed enzyme-prodrug therapy (ADEPT) is a complex two-phase system in which an enzyme is targeted
【进展|热点】Nature Immunology: 让T细胞动起来
, as antibody blockade of PD-1 or PD-L1 resulted in lower T cell motility, enhanced T cell–DC contacts and caused autoimmune diabetes. Blockade of the immunomodulatory receptor CTLA-4 did not alter T cell motility or abrogate tolerance. Thus, PD-1–PD-L1
技术资料暂无技术资料 索取技术资料
